Clinical Cell Culture
From Wikipedia, the free encyclopedia
| Type | Public company (ASX: CCE) |
|---|---|
| Founded | 1993 |
| Founder(s) | Fiona Wood |
| Headquarters | Cambridge; Perth, Western Australia; Coral Springs, Florida |
| Area served | Global |
| Key people | Andrew Cannon, Chief Executive |
| Industry | Surgical medicine |
| Products | Artificial skin |
| Services | Burns treatments |
| Website | http://www.clinicalcellculture.com/ |
Clinical Cell Culture (C3) ASX: CCE, is a company founded by Fiona Wood which aims to develop and market spray-on skin processes, especially for the treatment of skin trauma and burns victims.
It products are known as CellSpray and ReCell.
Clinical Cell Culture | C3 | is a publicly listed company on the Australian Stock Exchange(ASX), trading under the symbol CCE.[1]
In March 2007, the company announced a restructure and a new Chief Executive Officer following a previous half-year loss of $5 million.[2]
The company restructured and was renamed "Visiomed" in June 2008.[3]
[edit] References
- ^ ASX details
- ^ Clinical Cell Culture to tighten operations ABC News Online. March 29, 2007
- ^ http://www.visiomed.com.au/
[edit] External links
 |
This article about an Australian corporation or company is a stub. You can help Wikipedia by expanding it. |
|
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
